Chief executive of Array BioPharma resigns

Chairman Kyle Lefkoff will lead effort to replace Robert Conway

Robert Conway has resigned as chief executive of Array BioPharma, a US biotechnology company, for personal reasons. The board has appointed chairman Kyle Lefkoff to serve as executive chairman to oversee the company in the interim and lead the effort to identify a new chief executive.

Lefkoff said he will work with the Array management team to ensure a smooth transition and continued advancement of the company’s multiple clinical programmes in cancer and inflammation and supporting our many partnered programmes.

You may also like

Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Finance

Array BioPharma to cut jobs in restructure

Will focus on development of key clinical programmes
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Pharmaceutical
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
Bavarian Nordic secures four-year UK vaccine supply contract

Bavarian Nordic secures four-year UK vaccine supply contract

The agreement with the UK Health Security Agency will see the Danish vaccine manufacturer supply its MVA-BN mpox and smallpox vaccine, supporting the UK's long-term infectious disease preparedness
Pharmaceutical
Pharma’s silent sustainability risk and the supply chain fix

Pharma’s silent sustainability risk and the supply chain fix

Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
Subscribe now